-
Posted by
Two Blokes May 12 -
Filed in
Stock
-
3 views
Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manufacturing capacity and increased commercial infusions, potentially leading to a positive earnings surprise. Despite the Q1 setback, Iovance's early adoption, expanding treatment network, and international regulatory prospects indicate strong long-term growth potential.
